A Randomized, Multicenter, Double-Blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-Negativ
Posted Date: May 15, 2019
- Investigator: Trisha Wise-Draper
- Type of Study: Drug
The purpose of this study is to compare the effects of the study drug, palbociclib in combination with cetuximab against placebo in combination with cetuximab. Palbociclib is not approved to treat head and neck cancer, meaning it is an investigational drug for the purpose of this study.
Criteria:
To Be Eligible To Participate In This Study, Participants Must Have Head And Neck Cancer That Cannot
Keywords:
Pfizer A5481044, Cancer, Phase Ii, Head & Neck
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu